Suppr超能文献

通过调控宿主代谢来控制 COVID-19 负担。

Controlling the Burden of COVID-19 by Manipulating Host Metabolism.

机构信息

Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.

出版信息

Viral Immunol. 2022 Jan-Feb;35(1):24-32. doi: 10.1089/vim.2021.0150. Epub 2021 Dec 13.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by the coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause global health problems, but its impact would be minimized if the many effective vaccines that have been developed were available and in widespread use by all societies. This ideal situation is not occurring so other means of controlling COVID-19 are needed. In this short review, we make the case that manipulating host metabolic pathways could be a therapeutic approach worth exploring. The rationale for such an approach comes from the fact that viruses cause metabolic changes in cells they infect, effective host defense mechanisms against viruses requires the activity of one or more metabolic pathways, and that hosts with metabolic defects such as diabetes are more susceptible to severe consequences after COVID-19. We describe the types of approaches that could be used to redirect various aspects of host metabolism and the success that some of these maneuvers have had at controlling other virus infections. Manipulating metabolic activities to control the outcome of COVID-19 has to date received minimal attention. Manipulating host metabolism will never replace vaccines to control COVID-19 but could be used as an adjunct therapy to the extent of ongoing infection.

摘要

由冠状病毒 SARS-CoV-2 引起的 2019 年冠状病毒病(COVID-19)大流行继续给全球健康带来问题,但如果已开发的众多有效疫苗可供所有社会使用并广泛使用,其影响将最小化。这种理想情况并未发生,因此需要其他控制 COVID-19 的方法。在这篇简短的综述中,我们提出了一种观点,即操纵宿主代谢途径可能是一种值得探索的治疗方法。这种方法的基本原理是病毒会导致感染的细胞发生代谢变化,有效抵御病毒的宿主防御机制需要一种或多种代谢途径的活性,并且存在代谢缺陷(如糖尿病)的宿主在 COVID-19 后更容易受到严重后果的影响。我们描述了可以用来改变宿主代谢各个方面的方法类型,以及这些策略在控制其他病毒感染方面取得的部分成功。到目前为止,操纵代谢活动以控制 COVID-19 的结果几乎没有受到关注。操纵宿主代谢永远不会取代疫苗来控制 COVID-19,但可以在持续感染的范围内用作辅助治疗。

相似文献

1
Controlling the Burden of COVID-19 by Manipulating Host Metabolism.
Viral Immunol. 2022 Jan-Feb;35(1):24-32. doi: 10.1089/vim.2021.0150. Epub 2021 Dec 13.
2
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
3
Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Semin Thromb Hemost. 2020 Oct;46(7):796-803. doi: 10.1055/s-0040-1712157. Epub 2020 Jun 11.
4
Virus Infections and Host Metabolism-Can We Manage the Interactions?
Front Immunol. 2021 Feb 3;11:594963. doi: 10.3389/fimmu.2020.594963. eCollection 2020.
5
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
6
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.
Signal Transduct Target Ther. 2023 Jun 7;8(1):237. doi: 10.1038/s41392-023-01510-8.
7
SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion.
Viruses. 2022 Sep 8;14(9):1991. doi: 10.3390/v14091991.
8
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
9
Metabolic reprogramming and immune regulation in viral diseases.
Rev Med Virol. 2022 Mar;32(2):e2268. doi: 10.1002/rmv.2268. Epub 2021 Jun 27.
10
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015112. doi: 10.1002/14651858.CD015112.pub3.

引用本文的文献

1
Psychophysical therapy and underlying neuroendocrine mechanisms for the rehabilitation of long COVID-19.
Front Endocrinol (Lausanne). 2023 Sep 29;14:1120475. doi: 10.3389/fendo.2023.1120475. eCollection 2023.
3
Changes in the Urine Metabolomic Profile in Patients Recovering from Severe COVID-19.
Metabolites. 2023 Feb 28;13(3):364. doi: 10.3390/metabo13030364.
4
Metabolism of NK cells during viral infections.
Front Immunol. 2023 Jan 18;14:1064101. doi: 10.3389/fimmu.2023.1064101. eCollection 2023.
5
Obesity and COVID-19: What are the Consequences?
Horm Metab Res. 2022 Aug;54(8):496-502. doi: 10.1055/a-1878-9757. Epub 2022 Jun 20.
6
Long-COVID, Metabolic and Endocrine Disease.
Horm Metab Res. 2022 Aug;54(8):562-566. doi: 10.1055/a-1878-9307. Epub 2022 Jun 20.

本文引用的文献

1
Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
Open Forum Infect Dis. 2021 Oct 8;8(11):ofab512. doi: 10.1093/ofid/ofab512. eCollection 2021 Nov.
2
Modulating glutamine metabolism to control viral immuno-inflammatory lesions.
Cell Immunol. 2021 Dec;370:104450. doi: 10.1016/j.cellimm.2021.104450. Epub 2021 Oct 14.
3
Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy.
Metabolites. 2021 Oct 13;11(10):699. doi: 10.3390/metabo11100699.
4
Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19.
Cell Death Differ. 2021 Dec;28(12):3199-3213. doi: 10.1038/s41418-021-00892-y. Epub 2021 Oct 18.
5
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Front Immunol. 2021 Oct 1;12:752227. doi: 10.3389/fimmu.2021.752227. eCollection 2021.
7
Inhibiting Glucose Metabolism Results in Herpes Simplex Encephalitis.
J Immunol. 2021 Oct 1;207(7):1824-1835. doi: 10.4049/jimmunol.2100453. Epub 2021 Sep 1.
8
Chronic SARS-CoV-2, a Cause of Post-acute COVID-19 Sequelae (Long-COVID)?
Front Microbiol. 2021 Aug 2;12:724654. doi: 10.3389/fmicb.2021.724654. eCollection 2021.
9
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.
Lancet Rheumatol. 2021 Oct;3(10):e690-e697. doi: 10.1016/S2665-9913(21)00216-2. Epub 2021 Aug 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验